ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Board of Scientific Advisors discussion: Are peer reviewers correctly interpreting the guidelines?

March 19, 2004

DCPC advisors OK 16 Year Trial Of Screening Methods

February 15, 1991

In Brief: Barbara Britt Assumes ONS Presidency, O’Conner Is President-Elect; Kalt Joins NCI

May 25, 1990

AACI Says Fund Reductions Hurt Cancer Centers

March 24, 1978

Some NCI Advisors Tell GAO Congress “Jumped The Gun” In Creating Cancer Control Program

October 26, 1979

NCI-Approved Clinical Trials

September 29, 2006